Abstract
Obesity is associated with increased body fat composition and elevated risk of metabolic and cardiovascular disease. The activity of the renin-angiotensin system is generally increased in obesity and experimental evidence has shown that angiotensin influences appetite and metabolism as well as mechanisms that induce adipose tissue growth and metabolism in peripheral organs. This review summarises some of the key evidence from animal and human experiments that links the renin-angiotensin system to obesity and metabolic disease. This research has been greatly aided by the continuing development of new pharmaceuticals that inhibit the renin-angiotensin system. While their primary use is in the treatment of hypertension and heart failure, a range of experimental and clinical evidence indicates their potential use in the treatment of obesity and metabolic disease.
Keywords: Angiotensin converting enzyme, glucose metabolism, fat metabolism, Obesity, renin-angiotensin, metabolic disease, appetite, metabolism, hypertension, abdominal
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: The Role of Angiotensin in Obesity and Metabolic Disease
Volume: 11 Issue: 3
Author(s): Michael L. Mathai, Nora Chen, Lauren Cornall and Richard S. Weisinger
Affiliation:
Keywords: Angiotensin converting enzyme, glucose metabolism, fat metabolism, Obesity, renin-angiotensin, metabolic disease, appetite, metabolism, hypertension, abdominal
Abstract: Obesity is associated with increased body fat composition and elevated risk of metabolic and cardiovascular disease. The activity of the renin-angiotensin system is generally increased in obesity and experimental evidence has shown that angiotensin influences appetite and metabolism as well as mechanisms that induce adipose tissue growth and metabolism in peripheral organs. This review summarises some of the key evidence from animal and human experiments that links the renin-angiotensin system to obesity and metabolic disease. This research has been greatly aided by the continuing development of new pharmaceuticals that inhibit the renin-angiotensin system. While their primary use is in the treatment of hypertension and heart failure, a range of experimental and clinical evidence indicates their potential use in the treatment of obesity and metabolic disease.
Export Options
About this article
Cite this article as:
L. Mathai Michael, Chen Nora, Cornall Lauren and S. Weisinger Richard, The Role of Angiotensin in Obesity and Metabolic Disease, Endocrine, Metabolic & Immune Disorders - Drug Targets 2011; 11 (3) . https://dx.doi.org/10.2174/187153011796429853
DOI https://dx.doi.org/10.2174/187153011796429853 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vitamin D and Physical Performance in Athletes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Moderate Wine Consumption in the Prevention of Metabolic Syndrome and its Related Medical Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Long-term Results After Transcatheter Aortic Valve Implantation: What do we Know Today?
Current Cardiology Reviews Endothelial Progenitor Cells and Vascular Biology in Diabetes Mellitus: Current Knowledge and Future Perspectives
Current Diabetes Reviews Candidate Circulating Biomarkers for the Cardiovascular Disease Continuum
Current Pharmaceutical Design miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents
Current Cancer Drug Targets Proniosomes in Transdermal Drug Delivery
Current Pharmaceutical Design Platelets in Atherothrombosis: New and Evolving Roles
Current Pharmaceutical Design Recent Advances in Treatment Approaches of Mucopolysaccharidosis VI
Current Pharmaceutical Biotechnology Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms
Endocrine, Metabolic & Immune Disorders - Drug Targets Angiotensin Converting Enzyme Inhibitory Peptides Derived from Food Proteins: Biochemistry, Bioactivity and Production
Current Pharmaceutical Design Stem Cells in Stroke Repair: Current Success & Future Prospects
CNS & Neurological Disorders - Drug Targets Molecular Mechanisms Involved in the Aging of the T-cell Immune Response
Current Genomics Adenosine and Stroke: Maximizing the Therapeutic Potential of Adenosine as a Prophylactic and Acute Neuroprotectant
Current Neuropharmacology Discovery of Aroyl Piperazine Derivatives as I<sub>Kr</sub> & I<sub>Ks</sub> Dual Inhibitors for Cardiac Arrhythmia Treatment
Medicinal Chemistry Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives
Current Vascular Pharmacology Pulmonary Hypertension and Right Ventricular Dysfunction in Chronic Lung Diseases: New Pathobiologic Concepts
Current Respiratory Medicine Reviews Antiviral Therapy Targeting Viral Polymerase
Current Pharmaceutical Design Exploiting Cancer Metal Metabolism using Anti-Cancer Metal- Binding Agents
Current Medicinal Chemistry Cell and Gene Therapies in Cardiovascular Disease with Special Focus on the No Option Patient
Current Gene Therapy